Press release
CD137 Clinical Trials and Market Opportunity
Download Insight:
https://www.kuickresearch.com/report-cd137-gene-cd137-antibody-cd137-antibodies-cd137-marker-cd137-cancercd137-expressioncd137-ligand
The clinical trials exploring CD137 agonists focus on their ability to stimulate the immune system's natural defenses against cancer. By activating CD137, these therapies enhance T cell proliferation, improve survival, and foster the development of memory T cells that can provide long-lasting protection against tumor recurrence. Early-stage trials have shown promising results, with CD137 agonists demonstrating anti-tumor activity in cancers such as melanoma, lymphoma, and non-small cell lung cancer. These findings are encouraging for both researchers and companies involved in the development of CD137-targeted therapies.
Combination therapies featuring CD137 agonists are a particularly promising area of research. CD137 agonists are being tested alongside immune checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, with the goal of creating a synergistic effect that amplifies the immune response. In early clinical trials, this combination approach has shown potential in overcoming resistance to single-agent therapies, providing new hope for patients with cancers that do not respond well to existing treatments. The ability to combine CD137 agonists with other treatments not only expands the therapeutic possibilities but also enhances the market potential of these therapies.
The market opportunity for CD137-targeted therapies is significant, driven by the growing demand for immunotherapies that can provide more durable and effective cancer treatments. The immuno-oncology market is expected to see rapid growth in the coming years, with CD137-targeted therapies positioned to play a key role in this expansion. As clinical trials continue to show positive outcomes, pharmaceutical companies developing CD137 agonists are poised to capture a share of this lucrative market. The global cancer immunotherapy market was valued at over $100 billion in 2021, and the introduction of new, innovative therapies like CD137 agonists could significantly drive future growth.
In addition to their potential in cancer treatment, CD137 agonists may also offer opportunities in other therapeutic areas. Researchers are exploring the use of CD137 in autoimmune diseases, where modulating immune responses could help manage conditions such as rheumatoid arthritis and lupus. Expanding the application of CD137-targeted therapies beyond oncology could open up additional revenue streams for companies investing in this segment.
With the ongoing advancements in clinical trials and the growing interest in CD137 as a therapeutic target, the market opportunity for CD137 agonists is substantial. As more data becomes available, the potential for CD137-targeted therapies to revolutionize cancer treatment and beyond will only continue to grow. Pharmaceutical companies and investors focusing on this emerging area are well-positioned to capitalize on the expanding immunotherapy market, offering new hope for patients and unlocking significant commercial opportunities.
KuicK Research
Delhi
India
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CD137 Clinical Trials and Market Opportunity here
News-ID: 3651130 • Views: …
More Releases from KuicK Research
Future Directions in CD47 Research: Innovations and Clinical Translation
CD47, a protein that plays a critical role in immune evasion by tumor cells, has emerged as a key target in cancer research. Its ability to interact with signal regulatory protein alpha (SIRPα) on macrophages, delivering a "don't eat me" signal that prevents the phagocytosis of tumor cells, has made it a focal point for therapeutic development. As research into CD47 progresses, several innovative approaches and clinical translation efforts are…
Advances in Targeting CD137 for Tumor Immunotherapy
CD137 has become a central focus in the search for more effective cancer treatments, particularly in the realm of tumor immunotherapy. The receptor's role in enhancing immune cell activity makes it an attractive target for therapies that aim to harness the body's own defenses to combat cancer. Advances in targeting CD137 are rapidly expanding the possibilities for more personalized and potent immunotherapy strategies, offering new hope for patients and creating…
The Impact of CD137 on T Cell Activation and Immunity
CD137, also referred to as 4-1BB, plays a critical role in the regulation of immune responses, particularly through its influence on T cell activation. T cells are essential for the immune system's ability to recognize and eliminate cancer cells, making them a vital component of cancer immunotherapy. The activation of CD137 enhances the function and persistence of T cells, positioning it as a significant target in the fight against cancer.
Download…
The Mechanisms of Action of Targeted Antibodies in Cancer Therapy
Understanding the mechanisms of action of targeted antibodies is crucial for appreciating their role in cancer therapy and their potential to improve patient outcomes. Targeted antibodies are engineered to recognize and bind specific antigens on cancer cells, leading to their destruction through various mechanisms, including direct inhibition of growth signals, induction of apoptosis, and recruitment of immune cells.
One of the primary mechanisms by which monoclonal antibodies (mAbs) work is by…
More Releases for CD137
Recombinant Protein Market continues to expand with Biosimilars Applications
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used…
Tumor Necrosis Factor Receptor Superfamily Member 9: North America to Retain its …
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 35 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
To evaluate factors influencing Tumor Necrosis Factor Receptor Superfamily Member 9, Market Research Hub (MRH) has included a report titled “Tumor Necrosis Factor Receptor…
BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Sti …
Headquartered in Shirley, New York, the world’s reputed chemical supplier BOC Sciences announced to diversify its immune checkpoint inhibitors as well as nonspecific immune stimulation targets for scientific research targeting cancer immunotherapy (https://www.bocsci.com/tag/cancer-immunotherapy-36.html) on August 29, 2018.
Traditionally, surgery, chemotherapy and radiotherapy are the most widely chosen therapies in cancer treatment. However, in recent years, immunotherapy has attracted increasing attention among the research community. Immunotherapy agents do not directly…
Provecs Medical Announces Publication of Scientific Review of Gene Therapy in On …
-- Peer-reviewed paper in Human Gene Therapy provides comprehensive overview of using gene therapy to address multiple targets --
Hamburg (December 14, 2017) - Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the publication of a review highlighting the use of gene therapy approaches in immuno-oncology to address multiple targets with a single drug. The paper entitled “Immuno-Oncology - the Translational Runway…
Tumor Necrosis Factor Receptor Superfamily Member 9 -Pipeline Review, H2 2017
"The Report Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
According to the recently published report Tumor Necrosis Factor Receptor Superfamily Member 9-Pipeline Review, H2 2017; Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB…
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncol …
MarketResearchReports.Biz presents this most up-to-date research on "Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology"
Description
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM),…
